SOME BONE METABOLIC PARAMETERS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
https://doi.org/10.14412/1995-4484-2010-1165
Abstract
Objective: To define the specific features of bone metabolism and to estimate bone mineral density (BMD) in patients with early rheumatoid
arthritis (ERA).
Subjects and methods. Fifty-three patients (9 males and 44 females) with ERA were examined. Markers of bone metabolism markers were
assessed, by measuring the serum levels of osteocalcin and C-terminal telopeptides (bCrosslaps) by electrochemoluminescence immunoassay
and those of type II interleukin (IL) 1 receptor (IL1RII) and IL-6 by enzyme-linked immunosorbent assay. Bone mineral density
(BMD) was studied by distal forearm densitometry (dual-energy X-ray absorptiometry) on a DexaScan DX-10 apparatus. BMD was estimated
in postmenopausal women by the T-test and in men and premenopausal women by the Z-test, as well as by the absolute value of
BMD (g/cm2).
Results. In patients with ERA, the level of bCrosslaps was 0.50.3 ng/ml (p<0.05) and that of osteocalcin was 209.9 ng/ml (p>0.05),
which is accordingly higher and lower than the reference values. There were no changes in these parameters in relation to serogroup and Xray
disease stage. With higher ERA activity, there was a tendency for bCrosslaps to increase and osteocalcin to remain unchanged. There
was a tendency towards decreased IL1 RII and increased proinflammatory IL-6 levels. Correlation analysis revealed a correlation between
the value of BMD and the content of bCrosslaps and osteocalcin in patients with ERA and between the levels of IL-6 and bCrosslaps.
Regression analysis showed a significant impact of the parameters of the course of the disease and immunological parameters on BMD
changes and bone metabolism markers. Age and body mass index also affected the parameters of BMD in patients with ERA.
arthritis (ERA).
Subjects and methods. Fifty-three patients (9 males and 44 females) with ERA were examined. Markers of bone metabolism markers were
assessed, by measuring the serum levels of osteocalcin and C-terminal telopeptides (bCrosslaps) by electrochemoluminescence immunoassay
and those of type II interleukin (IL) 1 receptor (IL1RII) and IL-6 by enzyme-linked immunosorbent assay. Bone mineral density
(BMD) was studied by distal forearm densitometry (dual-energy X-ray absorptiometry) on a DexaScan DX-10 apparatus. BMD was estimated
in postmenopausal women by the T-test and in men and premenopausal women by the Z-test, as well as by the absolute value of
BMD (g/cm2).
Results. In patients with ERA, the level of bCrosslaps was 0.50.3 ng/ml (p<0.05) and that of osteocalcin was 209.9 ng/ml (p>0.05),
which is accordingly higher and lower than the reference values. There were no changes in these parameters in relation to serogroup and Xray
disease stage. With higher ERA activity, there was a tendency for bCrosslaps to increase and osteocalcin to remain unchanged. There
was a tendency towards decreased IL1 RII and increased proinflammatory IL-6 levels. Correlation analysis revealed a correlation between
the value of BMD and the content of bCrosslaps and osteocalcin in patients with ERA and between the levels of IL-6 and bCrosslaps.
Regression analysis showed a significant impact of the parameters of the course of the disease and immunological parameters on BMD
changes and bone metabolism markers. Age and body mass index also affected the parameters of BMD in patients with ERA.
References
1. <div><p>Насонов Е.Л., Скрипникова И.А., Насонова В.А. Остеопороз: ревматологические перспективы. Тер арх 1997;5:5-9.</p><p>Scuderi F. Effect of pro-inflammatory/antiinflammatory agents on cytokine secretion by peripheral blood mononuclear cells in rheumatoide arthritis and systemic lupus erythematosus. Autoimmunity 2003;36(2):71-7.</p><p>Тотров И.Н. Механизмы развития остеопороза у больных ревматоидным артритом: Автореф. дис. д-ра мед. наук. Ярославль, 2006.</p><p>Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. Под ред. О.М. Лесняк, Л.И. Беневоленской. Российская ассоциация остеопороза. М.: ГЭОТАР-Медиа, 2008.</p><p>Касумова К.А., Сатыбалдыев А.М., Смирнов А.В. Остеопороз и остеопоротические переломы у пациентов, заболевших ревматоидным артритом в пожилом возрасте. Науч-практич ревматол 2004;1:60-3.</p><p>Kaur K., Hardy R., Ahasan M.M. et al. Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss. Ann Rheum Dis, published online 22 Jun, 2009.</p><p>Haugeberg G., Green M.J., Quinn M. A. et al. Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis. Ann Rheum Dis 2006;65:736-40.</p><p>Насонов Е.Л., Скрипникова И.А., Беневоленская Л.И., Насонова В.А. Патогенез остеопороза: анализ иммунологических механизмов. Клин ревматол 1996;3:15-8.</p><p>Картамышева Н.Н., Чумакова О.В. Костное ремоделирование как модель межклеточных отношений. Нефрол и диализ 2004;6:43-6</p><p>Gь ller-Yь lksel M., Bijsterbosch J., Goekoop-Ruiterman Y.P.M. et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 2008;67:823-8.</p><p>Gь ller-Yь lksel M., Allaart C.F., Goekoop-Ruiterman Y.P.M. et al. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009;68:330-6.</p><p>Haugeberg G., Conaghan P.G., Quinn M., Emery P. Bone loss in active early rheumatoid arthritis patients treated with infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a twelve-month randomized, double blind, placebo-controlled study. Ann Rheum Dis, published online 21 Apr, 2009.</p><p>Hoff M., Haugeberg G., Оdegаrd S. et аl. Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow- up. Ann Rheum Dis 2009;68:324-9.</p><p>Gь ller-Yь lksel M., Bijsterbosch J., Goekoop-Ruiterman Y.P.M. et al. Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Ann Rheum Dis 2007;66:1508-12.</p><p>Лысак Н.В. Клинико-иммунологические особенности раннего ревматоидного артрита. Автореф. дис. канд. мед. наук. Оренбург, 2008.</p></div><br />
Review
For citations:
Antonova S.M., Bugrova O.V., Aleksandrova I.A., Ovchinnikova N.A. SOME BONE METABOLIC PARAMETERS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS. Rheumatology Science and Practice. 2010;48(4):48-53. (In Russ.) https://doi.org/10.14412/1995-4484-2010-1165
Views:
923
Email this article 